{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T19:59:58Z","timestamp":1783799998343,"version":"3.55.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G0F8316N"],"award-info":[{"award-number":["G0F8316N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Bedaquiline (BDQ) is a core drug for rifampicin-resistant tuberculosis (RR-TB) treatment. Accurate prediction of a BDQ-resistant phenotype from genomic data is not yet possible. A Bayesian method to predict BDQ resistance probability from next-generation sequencing data has been proposed as an alternative.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a qualitative study to investigate the decision-making of physicians when facing different levels of BDQ resistance probability. Fourteen semi-structured interviews were conducted with physicians experienced in treating RR-TB, sampled purposefully from eight countries with varying income levels and burden of RR-TB. Five simulated patient scenarios were used as a trigger for discussion. Factors influencing the decision of physicians to prescribe BDQ at macro-, meso- and micro levels were explored using thematic analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The perception and interpretation of BDQ resistance probability values varied widely between physicians. The limited availability of other RR-TB drugs and the high cost of BDQ hindered physicians from altering the BDQ-containing regimen and incorporating BDQ resistance probability in their decision-making. The little experience with BDQ susceptibility testing and whole-genome sequencing results, and the discordance between phenotypic susceptibility and resistance probability were other barriers for physicians to interpret the resistance probability estimates. Especially for BDQ resistance probabilities between 25% and 70%, physicians interpreted the resistance probability value dynamically, and other factors such as clinical and bacteriological treatment response, history of exposure to BDQ, and resistance profile were often considered more important than the BDQ probability value for the decision to continue or stop BDQ. In this grey zone, some physicians opted to continue BDQ but added other drugs to strengthen the regimen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study highlights the complexity of physicians' decision-making regarding the use of BDQ in RR-TB regimens for different levels of BDQ resistance probability.. Ensuring sufficient access to BDQ and companion drugs, improving knowledge of the genotype\u2013phenotype association for BDQ resistance, availability of a rapid molecular test, building next-generation sequencing capacity, and developing a clinical decision support system incorporating BDQ resistance probability will all be essential to facilitate the implementation of BDQ resistance probability in personalizing treatment for patients with RR-TB.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07865-7","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T08:04:09Z","timestamp":1669190649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bedaquiline resistance probability to guide treatment decision making for rifampicin-resistant tuberculosis: insights from a qualitative study"],"prefix":"10.1186","volume":"22","author":[{"given":"Pham Hien Trang","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Degefaye Zelalem","family":"Anlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anzaan","family":"Dippenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilyn Costa","family":"Concei\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasna","family":"Loos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Van Rie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"issue":"9","key":"7865_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","volume":"6","author":"K Schnippel","year":"2018","unstructured":"Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med. 2018;6(9):699\u2013706.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"7865_CR2","doi-asserted-by":"publisher","first-page":"1700387","DOI":"10.1183\/13993003.00387-2017","volume":"49","author":"SE Borisov","year":"2017","unstructured":"Borisov SE, Dheda K, Enwerem M, Romero Leyet R, Ambrosio L, Centis R, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387.","journal-title":"Eur Respir J"},{"issue":"1","key":"7865_CR3","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1186\/s12879-021-06666-8","volume":"21","author":"M-G Wang","year":"2021","unstructured":"Wang M-G, Wu S-Q, He J-Q. Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):970.","journal-title":"BMC Infect Dis"},{"key":"7865_CR4","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva 2020."},{"key":"7865_CR5","unstructured":"World Health Organization. Global tuberculosis report 2020. Geneva; 2020."},{"issue":"2","key":"7865_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.5588\/ijtld.16.0493","volume":"21","author":"L Guglielmetti","year":"2017","unstructured":"Guglielmetti L, Hewison C, Avaliani Z, Hughes J, Kiria N, Lomtadze N, et al. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. Int J Tuberc Lung Dis. 2017;21(2):167\u201374.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9","key":"7865_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239118","volume":"15","author":"D Gotham","year":"2020","unstructured":"Gotham D, McKenna L, Frick M, Lessem E. Public investments in the clinical development of bedaquiline. PLoS ONE. 2020;15(9): e0239118.","journal-title":"PLoS ONE"},{"issue":"1","key":"7865_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5588\/pha.18.0078","volume":"9","author":"CA Rodriguez","year":"2019","unstructured":"Rodriguez CA, Brooks MB, Guglielmetti L, Hewison C, Jachym MF, Lessem E, et al. Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study. Public Health Action. 2019;9(1):32\u201341.","journal-title":"Public Health Action"},{"issue":"1","key":"7865_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jinf.2019.09.006","volume":"80","author":"K Manalan","year":"2020","unstructured":"Manalan K, Green N, Arnold A, Cooke GS, Dedicoat M, Lipman M, et al. A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK. J Infect. 2020;80(1):38\u201341.","journal-title":"J Infect"},{"key":"7865_CR10","unstructured":"Partnership ST. StopTB Partnership\u2019s Global Drug Facility (STBP\/GDF) FAQs on bedaquiline price reduction and free goods 2020 [Available from: http:\/\/stoptb.org\/assets\/documents\/gdf\/drugsupply\/2020.07.06%20FAQs%20for%20bedaquiline%20price%20announcement.pdf."},{"issue":"5","key":"7865_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/fampra\/cmg516","volume":"20","author":"H Prosser","year":"2003","unstructured":"Prosser H, Walley T. New drug uptake: qualitative comparison of high and low prescribing GPs\u2019 attitudes and approach. Fam Pract. 2003;20(5):583\u201391.","journal-title":"Fam Pract"},{"key":"7865_CR12","doi-asserted-by":"crossref","unstructured":"Thomson RG, De Br\u00fan A, Flynn D, Ternent L, Price CI, Rodgers H, et al. Health Services and Delivery Research. Factors that influence variation in clinical decision-making about thrombolysis in the treatment of acute ischaemic stroke: results of a discrete choice experiment. Southampton (UK): NIHR Journals Library; 2017.","DOI":"10.3310\/hsdr05040"},{"issue":"7","key":"7865_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102135","volume":"9","author":"K Andries","year":"2014","unstructured":"Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS ONE. 2014;9(7): e102135.","journal-title":"PLoS ONE"},{"issue":"4","key":"7865_CR14","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/S2666-5247(20)30031-8","volume":"1","author":"C Nimmo","year":"2020","unstructured":"Nimmo C, Millard J, van Dorp L, Brien K, Moodley S, Wolf A, et al. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. The Lancet Microbe. 2020;1(4):e165\u201374.","journal-title":"The Lancet Microbe"},{"issue":"4","key":"7865_CR15","first-page":"e01677","volume":"58","author":"K Kaniga","year":"2020","unstructured":"Kaniga K, Aono A, Borroni E, Cirillo DM, Desmaretz C, Hasan R, et al. Validation of bedaquiline phenotypic drug susceptibility testing methods and breakpoints: a multilaboratory. Multicountry Study J Clin Microbiol. 2020;58(4):e01677-e1719.","journal-title":"Multicountry Study J Clin Microbiol"},{"key":"7865_CR16","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.ijid.2019.02.027","volume":"80","author":"CU K\u00f6ser","year":"2019","unstructured":"K\u00f6ser CU, Maurer FP, Kranzer K. \u201cThose who cannot remember the past are condemned to repeat\u201d: drug-susceptibility testing for bedaquiline and delamanid. Int J Infect Dis. 2019;80:S32\u20135.","journal-title":"Int J Infect Dis"},{"key":"7865_CR17","unstructured":"World Health Organization. Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Geneva; 2018. Contract No.: WHO\/CDS\/TB\/2018.5."},{"key":"7865_CR18","unstructured":"World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. Geneva 2021. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240028173."},{"key":"7865_CR19","doi-asserted-by":"crossref","unstructured":"Anlay DZ, Rivi\u00e8re E, Trang Tu PH, Abrams S, Van Rie A. A Bayesian approach to estimate the probability of resistance to bedaquiline in the presence of a genomic variant. bioRxiv. 2022:2022.08.30.505812.","DOI":"10.1101\/2022.08.30.505812"},{"key":"7865_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jclinepi.2020.12.021","volume":"131","author":"MJL Bours","year":"2021","unstructured":"Bours MJL. Bayes\u2019 rule in diagnosis. J Clin Epidemiol. 2021;131:158\u201360.","journal-title":"J Clin Epidemiol"},{"key":"7865_CR21","doi-asserted-by":"crossref","unstructured":"Sox HC, Higgins MC, Owens DK. Understanding New Information: Bayes\u2019 Theorem. Medical Decision Making Second ed: John Wiley & Sons, Ltd.; 2013. p. 61\u201392.","DOI":"10.1002\/9781118341544.ch4"},{"issue":"3","key":"7865_CR22","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/medu.14380","volume":"55","author":"J Thompson Burdine","year":"2021","unstructured":"Thompson Burdine J, Thorne S, Sandhu G. Interpretive description: a flexible qualitative methodology for medical education research. Med Educ. 2021;55(3):336\u201343.","journal-title":"Med Educ"},{"issue":"6","key":"7865_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"key":"7865_CR24","volume-title":"Prescribing in primary care: understanding what shapes GPs\u2019 prescribing choices and how might these be improved","author":"A Watt","year":"2007","unstructured":"Watt A, Tiessen J, Ling T, Rabinovich L. Prescribing in primary care: understanding what shapes GPs\u2019 prescribing choices and how might these be improved. Santa Monica: RAND Corporation; 2007."},{"issue":"1","key":"7865_CR25","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1186\/s12889-021-11427-y","volume":"21","author":"SEJ van de Berg","year":"2021","unstructured":"van de Berg SEJ, Pelzer PT, van der Land AJ, Abdrakhmanova E, Ozi AM, Arias M, et al. Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients. BMC Public Health. 2021;21(1):1404.","journal-title":"BMC Public Health"},{"issue":"5","key":"7865_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/fampra\/cmm040","volume":"24","author":"F Wood","year":"2007","unstructured":"Wood F, Simpson S, Butler CC. Socially responsible antibiotic choices in primary care: a qualitative study of GPs\u2019 decisions to prescribe broad-spectrum and fluroquinolone antibiotics. Fam Pract. 2007;24(5):427\u201334.","journal-title":"Fam Pract"},{"key":"7865_CR27","unstructured":"TORCH\u2014Tuberculosis Omics ResearCH 2022 [Available from: https:\/\/torch-consortium.com\/."},{"key":"7865_CR28","unstructured":"Scoggins A, Tiessen J, Ling T, Rabinovich L. Prescribing in primary care, Understanding what shapes GPs\u2019 prescribing choices and how might these be changed. Technical report prepared for the National Audit Office. RAND Corporation\u00a0\u2026; 2006."},{"issue":"1","key":"7865_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1471-2288-13-117","volume":"13","author":"NK Gale","year":"2013","unstructured":"Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13(1):117.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"7865_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/1525822X10388468","volume":"23","author":"JT DeCuir-Gunby","year":"2010","unstructured":"DeCuir-Gunby JT, Marshall PL, McCulloch AW. Developing and using a codebook for the analysis of interview data: an example from a professional development research project. Field Methods. 2010;23(2):136\u201355.","journal-title":"Field Methods"},{"issue":"1","key":"7865_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/160940691401300119","volume":"13","author":"RM Kahlke","year":"2014","unstructured":"Kahlke RM. Generic qualitative approaches: pitfalls and benefits of methodological mixology. Int J Qual Methods. 2014;13(1):37\u201352.","journal-title":"Int J Qual Methods"},{"issue":"519","key":"7865_CR32","first-page":"755","volume":"55","author":"J Hyde","year":"2005","unstructured":"Hyde J, Calnan M, Prior L, Lewis G, Kessler D, Sharp D. A qualitative study exploring how GPs decide to prescribe antidepressants. Br J Gen Pract. 2005;55(519):755\u201362.","journal-title":"Br J Gen Pract"},{"issue":"3","key":"7865_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/fampra\/19.3.285","volume":"19","author":"CA Chew-Graham","year":"2002","unstructured":"Chew-Graham CA, May CR, Perry MS. Qualitative research and the problem of judgement: lessons from interviewing fellow professionals. Fam Pract. 2002;19(3):285\u20139.","journal-title":"Fam Pract"},{"key":"7865_CR34","unstructured":"The World Bank. World Bank Country and Lending Groups 2022 [Available from: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups."},{"key":"7865_CR35","unstructured":"Johnson J. Bedaquiline Country Regulatory Status Overview 2021 [Available from: https:\/\/www.jnj.com\/_document\/bedaquiline-country-regulatory-status-overview?id=0000016e-0467-db13-a9ef-566f1a520000."},{"issue":"10","key":"7865_CR36","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","volume":"200","author":"P Nahid","year":"2019","unstructured":"Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of drug-resistant tuberculosis. An Official ATS\/CDC\/ERS\/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019;200(10):e93\u2013142.","journal-title":"Am J Respir Crit Care Med"},{"key":"7865_CR37","unstructured":"NHS England Specialised Services Clinical Reference Group for Infectious Diseases. Treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid. NHS England; 2021. Contract No.: 201203P."},{"issue":"1","key":"7865_CR38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s40506-019-0182-3","volume":"11","author":"D Jarovsky","year":"2019","unstructured":"Jarovsky D. Treatment of tuberculosis in Brazil\u2014past, present, and future challenges. Curr Treat Options Infect Dis. 2019;11(1):58\u201372.","journal-title":"Curr Treat Options Infect Dis"},{"key":"7865_CR39","unstructured":"Ministry of Health\u2014Ethiopia. Guidelines for Clinical and Programmatic Management of TB, TB\/HIV, DR-TB and Leprosy in Ethiopia. 7th ed. Addis Ababa, Ethiopia, 2021."},{"issue":"3","key":"7865_CR40","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1136\/thoraxjnl-2019-214004","volume":"76","author":"T Mugwagwa","year":"2021","unstructured":"Mugwagwa T, Abubakar I, White PJ. Using molecular testing and whole-genome sequencing for tuberculosis diagnosis in a low-burden setting: a cost-effectiveness analysis using transmission-dynamic modelling. Thorax. 2021;76(3):281\u201391.","journal-title":"Thorax"},{"key":"7865_CR41","first-page":"1","volume":"2021","author":"K Soetaert","year":"2019","unstructured":"Soetaert K, Ceyssens P-J, Boarbi S, Bogaerts B, Delcourt T, Vanneste K, et al. Retrospective evaluation of routine whole genome sequencing of Mycobacterium tuberculosis at the Belgian National Reference Center. Acta Clin Belg. 2019;2021:1\u20138.","journal-title":"Acta Clin Belg"},{"issue":"9","key":"7865_CR42","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41579-019-0214-5","volume":"17","author":"CJ Meehan","year":"2019","unstructured":"Meehan CJ, Goig GA, Kohl TA, Verboven L, Dippenaar A, Ezewudo M, et al. Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nat Rev Microbiol. 2019;17(9):533\u201345.","journal-title":"Nat Rev Microbiol"},{"issue":"6","key":"7865_CR43","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1128\/JCM.00298-17","volume":"55","author":"J Shea","year":"2017","unstructured":"Shea J, Halse TA, Lapierre P, Shudt M, Kohlerschmidt D, Van Roey P, et al. Comprehensive whole-genome sequencing and reporting of drug resistance profiles on clinical cases of Mycobacterium tuberculosis in New York State. J Clin Microbiol. 2017;55(6):1871\u201382.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"7865_CR44","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3201\/eid2703.204418","volume":"27","author":"HZ Farooq","year":"2021","unstructured":"Farooq HZ, Cirillo DM, Hillemann D, Wyllie D, van der Werf MJ, K\u00f6dm\u00f6n C, et al. Limited capability for testing Mycobacterium tuberculosis for susceptibility to new drugs. Emerg Infect Dis. 2021;27(3):985\u20137.","journal-title":"Emerg Infect Dis"},{"key":"7865_CR45","doi-asserted-by":"publisher","first-page":"e604","DOI":"10.1016\/S2666-5247(21)00175-0","volume":"2","author":"N Ismail","year":"2021","unstructured":"Ismail N, Rivi\u00e8re E, Limberis J, Huo S, Metcalfe JZ, Warren RM, et al. Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis. Lancet Microbe. 2021;2:e604.","journal-title":"Lancet Microbe."},{"issue":"20","key":"7865_CR46","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJM198005153022003","volume":"302","author":"SG Pauker","year":"1980","unstructured":"Pauker SG, Kassirer JP. The threshold approach to clinical decision making. N Engl J Med. 1980;302(20):1109\u201317.","journal-title":"N Engl J Med"},{"issue":"10","key":"7865_CR47","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/cid\/cix992","volume":"66","author":"TVA Nguyen","year":"2017","unstructured":"Nguyen TVA, Anthony RM, Ba\u00f1uls A-L, Nguyen TVA, Vu DH, Alffenaar J-WC. Bedaquiline resistance: its emergence, mechanism, and prevention. Clin Infect Dis. 2017;66(10):1625\u201330.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"7865_CR48","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S1473-3099(22)00007-X","volume":"22","author":"GP Mishra","year":"2022","unstructured":"Mishra GP, Mulani J. Implications of bedaquiline-resistant tuberculosis. Lancet Infect Dis. 2022;22(2):166.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"7865_CR49","doi-asserted-by":"publisher","first-page":"1702480","DOI":"10.1183\/13993003.02480-2017","volume":"51","author":"T Masini","year":"2018","unstructured":"Masini T, Hauser J, Kuwana R, Nhat Linh N, Jaramillo E. Will regulatory issues continue to be a major barrier to access to bedaquiline and delamanid? Eur Respir J. 2018;51(3):1702480.","journal-title":"Eur Respir J"},{"key":"7865_CR50","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.2147\/IDR.S256128","volume":"13","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Liu X, Yang L, Zhang G, Gu Z, Chen Z, et al. Barriers and strategies: a review of access to affordable multi-drug resistant tuberculosis medication in China. Infect Drug Resist. 2020;13:3679\u201387.","journal-title":"Infect Drug Resist."},{"key":"7865_CR51","volume-title":"Introduction of bedaquiline for the treatment of multi-drug resistant tuberculosis at country level: implementation plan","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Introduction of bedaquiline for the treatment of multi-drug resistant tuberculosis at country level: implementation plan. Geneva: Switzerland; 2015."},{"key":"7865_CR52","doi-asserted-by":"crossref","unstructured":"Furin J, Brigden G, Lessem E, Rich M, Vaughan L, Lynch S. Global progress and challenges in implementing new medications for treating multidrug-resistant tuberculosis. Emerg Infect Dis. 2016;22(3).","DOI":"10.3201\/eid2203.151430"},{"issue":"10","key":"7865_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002896","volume":"16","author":"G Brigden","year":"2019","unstructured":"Brigden G, Nhung NV, Skrahina A, Ndjeka N, Falzon D, Zignol M. Advances in clinical trial design for development of new TB treatments\u2014translating international tuberculosis treatment guidelines into national strategic plans: experiences from Belarus, South Africa, and Vietnam. PLoS Med. 2019;16(10): e1002896.","journal-title":"PLoS Med"},{"key":"7865_CR54","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.ijid.2019.01.040","volume":"80","author":"S Tiberi","year":"2019","unstructured":"Tiberi S, Pontali E, Tadolini M, D\u2019Ambrosio L, Migliori GB. Challenging MDR-TB clinical problems\u2014the case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs. Int J Infect Dis. 2019;80:S68\u201372.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"7865_CR55","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12911-022-01790-0","volume":"22","author":"L Verboven","year":"2022","unstructured":"Verboven L, Calders T, Callens S, Black J, Maartens G, Dooley KE, et al. A treatment recommender clinical decision support system for personalized medicine: method development and proof-of-concept for drug resistant tuberculosis. BMC Med Inform Decis Mak. 2022;22(1):56.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"4","key":"7865_CR56","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1473-3099(21)00470-9","volume":"22","author":"NA Ismail","year":"2022","unstructured":"Ismail NA, Omar SV, Moultrie H, Bhyat Z, Conradie F, Enwerem M, et al. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect Dis. 2022;22(4):496\u2013506.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"7865_CR57","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41533-020-0179-x","volume":"30","author":"IS Pradipta","year":"2020","unstructured":"Pradipta IS, Houtsma D, van Boven JFM, Alffenaar J-WC, Hak E. Interventions to improve medication adherence in tuberculosis patients: a systematic review of randomized controlled studies. Npj Prim Care Respir Med. 2020;30(1):21.","journal-title":"Npj Prim Care Respir Med."},{"issue":"3","key":"7865_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044687","volume":"11","author":"LS Peetluk","year":"2021","unstructured":"Peetluk LS, Ridolfi FM, Rebeiro PF, Liu D, Rolla VC, Sterling TR. Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults. BMJ Open. 2021;11(3): e044687.","journal-title":"BMJ Open"},{"key":"7865_CR59","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/j.ijid.2021.03.033","volume":"113","author":"C Lam","year":"2021","unstructured":"Lam C, Martinez E, Crighton T, Furlong C, Donnan E, Marais BJ, et al. Value of routine whole genome sequencing for Mycobacterium tuberculosis drug resistance detection. Int J Infect Dis. 2021;113:S48\u201354.","journal-title":"Int J Infect Dis"},{"key":"7865_CR60","unstructured":"World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. Geneva. 2018."},{"issue":"4","key":"7865_CR61","doi-asserted-by":"publisher","first-page":"bbaa246","DOI":"10.1093\/bib\/bbaa246","volume":"22","author":"E Rivi\u00e8re","year":"2021","unstructured":"Rivi\u00e8re E, Heupink TH, Ismail N, Dippenaar A, Clarke C, Abebe G, et al. Capacity building for whole genome sequencing of Mycobacterium tuberculosis and bioinformatics in high TB burden countries. Brief Bioinform. 2021;22(4):bbaa246.","journal-title":"Brief Bioinform"},{"issue":"4","key":"7865_CR62","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000433518","volume":"18","author":"F Tekola-Ayele","year":"2015","unstructured":"Tekola-Ayele F, Rotimi CN. Translational genomics in low- and middle-income countries: opportunities and challenges. Public Health Genomics. 2015;18(4):242\u20137.","journal-title":"Public Health Genomics"},{"key":"7865_CR63","doi-asserted-by":"crossref","unstructured":"Jouet A, Gaudin C, Badalato N, Allix-B\u00e9guec C, Duthoy S, Ferr\u00e9 A, et al. Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs. Eur Respir J. 2021;57(3).","DOI":"10.1183\/13993003.02338-2020"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07865-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07865-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07865-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T08:04:46Z","timestamp":1669190686000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07865-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7865"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07865-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"7 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Research Ethics Committee of the University Hospital of the University of Antwerp, Belgium (Reference number 21\/06\/093). The study was conducted in compliance with the Declaration of Helsinki. All participants provided electronic informed consent prior to study participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"876"}}